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Abstract
Background: Accurate and timely diagnosis of malaria is essential for disease management and surveillance. Thin
and thick blood smear microscopy and malaria rapid diagnostic tests (RDTs) are standard malaria diagnostics, but
both methods have limitations. The novel automated hematology analyzer XN-30 provides standard complete
blood counts (CBC) as well as quantification of malaria parasitemia at the price of a CBC. This study assessed the
accuracy of XN-30 for malaria detection in a controlled human malaria infection (CHMI) study and a phase 3
diagnostic accuracy study in Burkina Faso.
Methods: Sixteen healthy, malaria-naive CHMI participants were challenged with five Plasmodium falciparum-infected
mosquitoes. Blood was sampled daily for XN-30, blood smear microscopy, and malaria qPCR. The accuracy study
included patients aged > 3months presenting with acute febrile illness. XN-30, microscopy, and rapid diagnostic tests
(HRP-2/pLDH) were performed on site; qPCR was done in retrospect. The malaria reference standard was microscopy,
and results were corrected for sub-microscopic cases.
Results: All CHMI participants became parasitemic by qPCR and XN-30 with a strong correlation for parasite density
(R2 = 0.91; p < .0001). The XN-30 accurately monitored treatment and allowed detection of recrudescence. Out of 908
patients in the accuracy study, 241 had microscopic malaria (density 24–491,802 parasites/μL). The sensitivity and
specificity of XN-30 compared to microscopy were 98.7% and 99.4% (PPV = 98.7%, NPV = 99.4%). Results were corrected
for qPCR-confirmed sub-microscopic cases. Three microscopy-confirmed cases were not detected by XN-30. However,
XN-30 detected 19/134 (14.2%) qPCR-confirmed cases missed by microscopy. Among qPCR-confirmed cases, XN-30
had a higher sensitivity (70.9% versus 66.4%; p = .0009) and similar specificity (99.6% versus 100%; p = .5) as microscopy.
The accuracy of XN-30 for microscopic malaria was equal to or higher than HRP-2 and pLDH RDTs, respectively.
Conclusions: The XN-30 is a novel, automated hematology analyzer that combines standard hemocytometry with
rapid, objective, and robust malaria detection and quantification, ensuring prompt treatment of malaria and malaria
anemia and follow-up of treatment response.
Trial registration: Both trials were registered on clinicaltrials.gov with respective identifiers NCT02836002 (CHMI trial)
and NCT02669823 (diagnostic accuracy study).
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Background
Malaria remains a major cause of morbidity and mortal-
ity around the world. Sub-Saharan Africa is most af-
fected with Plasmodium falciparum accounting for 99%
of estimated cases [1]. Timely and accurate diagnosis of
malaria is essential for disease management and control
[2]. Thin and thick blood smear microscopy (further re-
ferred to as microscopy) and malaria rapid diagnostic
tests (RDTs) are standard malaria diagnostics in endemic
areas. RDTs have significantly improved the use of diag-
nostics for malaria diagnosis, accounting for 74% of
diagnostic tests performed among suspected cases in
2015 [3]. Both techniques provide challenges in clinical
practice: RDTs are antigen-directed and relative to their
design, can neither quantify malaria parasitemia, nor
allow monitoring of treatment response, prerequisites to
manage severe malaria. Additionally, RDTs cannot dis-
tinguish current from recently treated infections [4].
Consequently, false-positive results may be misinter-
preted as treatment failure [5]. WHO therefore reserves
a role for microscopy, which is however labor-intensive
and its quality is heavily observer-dependent. Molecular
tests are complex to perform, require highly trained
personnel, and are relatively expensive, limiting its gen-
eral use.
The XN-30 (Sysmex, Kobe, Japan) is a novel auto-
mated hematology analyzer and malaria diagnostic that
directly detects and quantifies Plasmodium parasites
(falciparum and non-falciparum) in blood using violet
laser technology [6–8]. Our study aimed to evaluate the
accuracy of the XN-30 for the detection of Plasmodium
falciparum malaria. First, we assessed its performance in
healthy participants in whom low-density parasitemia
was induced in a controlled human malaria infection
(CHMI) study. To establish the performance under field
conditions, we then performed a phase 3 diagnostic ac-
curacy study among febrile patients in Burkina Faso.
Methods
Controlled human malaria infection (CHMI)
The ability of the XN-30 to detect low-density sexual
and asexual parasitemia and monitoring of treatment
was studied in a CHMI trial (ClinicalTrials.gov,
NCT02836002). Details and results of the primary objec-
tives of this study have recently been published [9]. Eth-
ylenediaminetetraacetic acid (EDTA)-anticoagulated
venous blood was collected twice daily for XN-30, and
results were compared with qPCR for asexual- and
qRT-PCR for sexual P. falciparum parasites. Both tech-
niques are described in detail elsewhere [9].
Diagnostic accuracy study
This prospective, double-blinded, phase 3 diagnostic
accuracy study (ClinicalTrials.gov, NCT02669823) was
performed at the Clinical Research Unit of Nanoro
(CRUN) [10]. The primary objectives were (i) to as-
sess the diagnostic sensitivity and specificity of the
XN-30 to detect malaria parasitemia in children and
adults with an acute febrile illness against thick blood
smear microscopy or qPCR in case of a negative thick
smear or incongruent results of XN-30 and micros-
copy and (ii) to assess the diagnostic accuracy of the
Infection Manager System (IMS) for the detection of
bacterial bloodstream infection in a malaria-endemic
area. The secondary objective was to compare the ac-
curacy of the XN-30 analyzer to diagnose malaria
compared to malaria RDT. The results of the IMS are
reported elsewhere to increase legibility.
Procedures
Nanoro is a rural area of Burkina Faso which is hy-
perendemic for Plasmodium falciparum, though
Plasmodium ovale and Plasmodium malariae are
sporadically found [11]. Participants were enrolled be-
tween March 2016 and June 2017 at the “Centre
Medicale avec Antenne Chirurgicale” (CMA) of
Nanoro, to which CRUN is affiliated. Consecutive
patients of 3 months and older suspected of acute fe-
brile illness were screened for eligibility. Patients were
eligible if they had a measured temperature of ≥ 38.0 °
C or ≤ 35.5 °C, or a reported history of fever up to
48 h prior to presentation, or suspicion of severe in-
fection with signs of severe clinical illness. Patients
with fever lasting more than 7 days were excluded.
Upon inclusion, 2–5 mL EDTA anti-coagulated blood
was obtained and analyzed within 1 h after sampling.
Laboratory analyses were performed and interpreted
by experienced laboratory technicians who were
blinded to clinical data. Patients were followed daily
during hospitalization, and follow-up samples were
taken if clinically indicated. Another follow-up sample
was taken at approximately 2 weeks after inclusion.
Data was collected on case report forms (CRFs) and
entered into a secure database (RedCap, Vanderbilt
University, Nashville, USA) after conformity check by a
medical doctor. Entered data were checked against the
CRFs by a data manager. Approximately 10 % of partici-
pant study files were checked by an independent moni-
tor. Results from qPCR were entered into an Excel
(Microsoft, Washington, USA) database and merged
with the principal database. The researchers were
blinded to the XN-30 until the clinical database was
locked. Interpretation of the index test was done by
blinded researchers after inclusion was completed. La-
boratory procedures were standardized; quality controls
were performed according to good clinical and labora-
tory practices (GCLP) guidelines.
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Index test: XN-30
The XN-30 is an automated hematology analyzer (Sysmex
Corporation, Kobe, Japan) which can be used for malaria
detection as described in detail elsewhere [6]. The analyzer
aspirates and dilutes blood samples in a diluent solution
(CELLPACK DCL). Subsequently, the nucleic acids are
stained with a staining solution (Fluorocell M) along with
a lysis solution (LysercellM). Infected red blood cells
(iRBC) and white blood cells (WBC) are detected by
a violet semiconductor 405 nm laser beam. Parasit-
emia percentage is calculated by the ratio of infected-
and uninfected red blood cells. Output data separately
reports a complete blood count (CBC), the presence
of gametocytes and parasitemia—both as a percentage
of infected red blood cells (MI-RBC%) and absolute
parasite density (MI-RBC#) expressed as parasites/μL.
The data is automatically determined by analyzing
scatter grams plotted three dimensionally with
forward-side scattered light, side scattered light, and
side fluorescent light. iRBC are visible as a separate
RBC population on the scattergram (Fig. 1). In case
of abnormal scatter gram distribution, the malaria re-
sult is reported as “inconclusive.”
The analyzer aspirates approximately 60 μL whole
blood per analysis; results are available within 1 min.
XN-30 will be made for global distribution, and the price
of a measurement is expected to be comparable to regu-
lar hemocytometry [6]). No formal quantification limit
was applied for XN-30 for the CHMI study. In the diag-
nostic accuracy study, XN-30 values of ≥ 20 MI-RBC/μL
with at least 5% ring stages were considered positive.
Validated hemocytometry data were used for clinical
care, all experimental data were kept blinded.
Reference tests: malaria diagnostics
Both RDT and microscopy were performed using
EDTA-anticoagulated blood. Thick and thin blood films
were examined for the presence of Plasmodium parasites
according to WHO procedures [12]. Results were expressed
as asexual parasites per microliter using the patients’ WBC
count. The Plasmodium species and presence of gameto-
cytes were also recorded. Slides were viewed by two inde-
pendent microscopists. Presence of one or more
Plasmodium parasites was considered positive. In case of
discrepancies, the result of a third microscopist was
decisive.
Fig. 1 Forward sideward scatter of patient with and without malaria and gametocytes as recorded by the XN-30
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SD Bioline Malaria Ag-P.f (HRP2/pLDH) (Standard
Diagnostics, Inc., Gyeonggi-do, Republic of Korea) was
performed according to the manufacturer’s instructions.
Five microliters of venous blood was inoculated on the
RDT cassette. After 5 and 15min, the test line reactivity
of the Plasmodium falciparum histidine-rich protein-2
(HRP-2) and pan-Plasmodium species parasite-lactate
dehydrogenase (pLDH) were scored, whereby any visible
test line was considered positive. Results for pLDH and
HRP-2 were recorded separately. Quantitative PCR
(qPCR) targeting the multicopy 18S rRNA gene was per-
formed in retrospect at the Department of Microbiology
of Radboud University Medical Centre, the Netherlands,
using 200 μL blood per patient using previously
Fig. 2 Diagnostic performance of XN-30 in CHMI model expressed as (a) line graph and (b) scatterplot
Fig. 3 Parasite density curves of participants with recrudescent infections. The parasite density treatment threshold of 5 p/uL is indicated with a
grey line
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described methods [13]. The lower level of detection of
qPCR was 0.05 parasites per microliter (p/μL).
Case definitions, data management, and statistical
analysis
Malaria parasitemia was defined as the presence of one or
more parasites in the asexual stage in malaria microscopy
or a malaria qPCR result over 0.05 p/μL in the diagnostic
accuracy study. In case only gametocytes were observed,
microscopy was considered negative. Severe malaria was
defined according to WHO criteria 2014 [14].
A statistical plan was made before data inspection. Ana-
lyses were done using Stata 14 (Stata Corp, College Station,
TX, USA). Patients with missing data on either reference
test, index test, or qPCR were excluded from the analysis.
In the case of inconclusive index test results due to an ab-
normal scattergram distribution, the result was reported as
“inconclusive.” Differences in proportions, medians, or
means were compared using respectively the chi-square
test, two-tailed Fisher’s exact test, or Mann-Whitney U test
in case of not normally distributed data. Sensitivity, specifi-
city, positive predictive value (PPV), and negative predictive
value (NPV) were assessed using the STATA diagt-package.
A receiver operation characteristics (ROC) curve analysis
was done to assess the area under the curve (AUC). Linear
regression analyses were done to assess the correlation in
parasite densities between qPCR, malaria thick smear, and
XN-30. Comparative analyses of sensitivity and specificity
were done using a McNemar test and reported as test ratio
with significance level. A significance level of 5% was used
for all analyses.
Results
Controlled human malaria infection
We assessed the diagnostic accuracy of XN-30 in 16
healthy participants exposed to low-density parasitemia
during a CHMI (Additional file 3: Figure S1). All partici-
pants developed parasitemia between day 6 and 12
Fig. 4 Patient flow of prospective diagnostic validation study in Nanoro, Burkina Faso, excluding patients with incomplete data
Post et al. BMC Medicine          (2019) 17:103 Page 5 of 12
post-infection, as determined by qPCR. The geometric
mean peak parasitemia density was 21 p/μL. Figure 2a
shows parasitemia dynamics over time as quantified
by the XN-30 analyzer and by qPCR. The quantitative
data shows a strong correlation between the XN-30
and qPCR (R2 = 0.91; p < .0001) (Fig. 2b). The XN-30
was able to monitor treatment and detect recrudes-
cent infections (Fig. 3). The positive cutoff of the
XN-30 was 8.1 p/μL as defined by the mean of all
negative qPCR samples + 3 SD. Gametocyte densities
in CHMI were too low to be detected by microscopy
or XN-30 (< 1.3 gametocytes/μL). In vitro experiments
were performed to estimate the limit of detection of
mature gametocytes and test the stability of the
samples when measured by XN-30 (Additional file 4:
Figure S2 and Additional file 6: Figure S4). Sample
quantification remained accurate up to 6 h after
sampling, at room temperature (Additional file 5:
Figure S3).
Diagnostic accuracy study
We assessed the diagnostic accuracy under field condi-
tions in a malaria hyperendemic region in Burkina Faso.
A total of 1213 eligible patients presented at CMA
Nanoro, of whom 930 were included (Fig. 4). Fourteen
patients were excluded from analysis due to inadequate
sample storage or evident sample mismatch. For eight
patients, the PCR data was not available due to a short-
age of sampled blood. Additionally, in 71 patients (7.8%),
the XN-30 scattergram was abnormally distributed and
therefore reported as “inconclusive.” There were signifi-
cantly more patients aged 0–2 and patients with malnu-
trition among this group. Malaria was significantly less
prevalent (Additional file 1: Table S1).
Baseline characteristics for all included patients are
presented by age group in Table 1. The percentage of pa-
tients who were pre-treated with antimalarials prior to
admission ranged between 25.8% (84/335) in adults and
46.1% (83/180) in children 2–5 years old. Severe malaria
Table 1 Baseline characteristics (n = 908)
Children Adults
0–2 years 2–5 years 5–15 years > 15 years
n = 266 n = 180 n = 127 n = 335
Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Age distribution (months, years) 12 (8–17) months 36 (28–46) months 8 (6–10) years 41 (29–59) years
Male: female ratio 1.5 1.5 1.3 1.2
Fever (days) 3 (2–3) 3 (2–3) 3 (2–4) 3 (2–4)
Temperature (°C) 38.5 (38.0–39.4) 38.3 (37.9–39.4) 38.2 (37.7–39.0) 38.3 (38.0–39.0)
Systolic BP (mm/Hg) 98 (89–106) 98 (90–108) 102 (95–112) 108 (96–124)
Diastolic BP (mm/Hg) 61 (53–65) 62 (56–69) 63 (59–75) 66 (60–76)
MAP (mm/Hg) 73 (66–79) 75 (67–81) 80 (72–87) 83 (72–92)
Pulse (min) 125 (112–133) 123 (108–135) 116 (100–125) 104 (96–119)
Respiratory rate (min) 35 (32–42) 32 (30–38) 29 (26–30) 27 (26–28)
Hemoglobin (g/dL) 7.8 (5.6–10.0) 8.6 (6.5–10.7) 9.4 (7.8–11.6) 10.3 (8.4–12.8)
WBC (cells × 103/μL) 13.1 (10.0–19.4) 11.2 (7.9–16.5.) 10.6 (7.4–16.6) 7.9 (5.5–12.8)
Platelets (cells × 103/μL) 277 (124–452) 232 (126–358) 271 (181–372) 237 (156–337)
n (%) n (%) n (%) n (%)
Antimalarials taken in past 2 weeks 93 (34.2) 83 (46.1) 54 (42.1) 86 (25.8)
HIV (confirmed before inclusion) 1 (0.4) 2 (1.1) 3 (2.3) 11 (3.3)
Malnourished1 112 (43.4) 70 (41.2) 47 (41.6) 84 (28.6)
Severe anaemia2 87 (32.7) 50 (27.8) 33 (25.8) 72 (27.7)
Severe malaria 56 (21.0) 47 (26.1) 12 (9.3) 5 (1.5)
Severe anemia 28 (50.0) 15 (31.9) 8 (66.7) 4 (80.0)
Cerebral malaria 8 (14.3) 10 (21.3) 3 (25.0) 0
Respiratory distress 2 (3.6) 4 (8.5) 0 0
Parasitemia > 150.000 p/μL 18 (32.1) 18 (38.3) 1 (8.3) 1 (20.0)
BP blood pressure, MAP mean arterial pressure, WBC white blood cells
1Based on Z-scores for children < 5 and BMI for older patients, data available for respectively 258, 170, 113, and 294 patients per age group
2Based on WHO criteria for severe anemia
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was detected in 120 (50.0%) patients with microscopic-
ally confirmed malaria, of whom 55 (45.6%) fulfilled the
criteria of severe anemia. These high numbers are in line
with previously reported results [11] and are likely
caused by the function of CMA as a district referral hos-
pital for complicated disease. In total, 411 follow-up
samples were taken: 59 during hospitalization and 352 at
2-week follow-up.
The results of malaria diagnostics are presented in
Table 2. A total of 240 patients (26.4%) had positive mi-
croscopy with parasite densities ranging from 24 to
500,000 p/μL (median 15,614; IQR 745–76,901); 374
patients (41.2%) had a positive qPCR. Sub-microscopic
parasitemia (positive qPCR with negative microscopy)
was detected in 134 patients (14.8%) with densities ran-
ging from 0.05 to 102.8 p/μL (median 0.68; IQR 0.13–
3.1). Six microscopy-positive cases were not detected
by qPCR. RDTs were positive in 396 patients; in more
than half of the cases, both pLDH and HRP-2 were
positive. XN-30 recorded 255 cases of malaria with a
median parasite density of 12,390 p/μL (IQR 650–
88,656).
Tables 3 and 4 present the diagnostic sensitivity, speci-
ficity, PPV, and NPV for XN-30 against microscopy and
qPCR. Figure 5 shows the corresponding ROC curves at
the cutoff value of 20 p/μL . The sensitivity and specifi-
city of XN-30 against microscopy were 98.7% and 96.5%,
respectively. In 21 cases, the XN-30 indicated parasit-
emia whereas microscopy was deemed negative; 19/21
cases were later confirmed as sub-microscopic parasit-
emia by qPCR. Three samples were false negatives: two
cases had low parasite densities (< 20 p/μL in qPCR), the
third had a high parasite density and was suspected to be
a sample mix-up based on discrepancies in CBC between
the XN-30 and a second hematology analyzer used for
clinical care. After correction for sub-microscopic malaria,
the sensitivity and specificity of the XN-30 increased to
98.8% and 99.7% respectively with a PPV of 99.2% and an
NPV of 99.5% (AUC 0.99).
Table 4 presents the diagnostic accuracy for XN-30
and microscopy compared to qPCR. The XN-30 had a
significantly higher sensitivity than microscopy to detect
qPCR-confirmed parasitemia (70.9% versus 66.4%, p= .0009)
whereas specificity did not differ between both tests (99.6%
versus 100%, p= .5). The cutoff value of best fit to qPCR in
the current dataset was a parasite density of 26 p/μL, which
gave similar results to the proposed cutoff value (sensitivity
69.5%, specificity 98.8%) (Additional file 2: Table S2,
Additional file 6: Figure S4).
A secondary objective was to compare the diagnostic
performance of XN-30 to diagnose malaria parasitemia
against two RDTs. Table 5 shows the diagnostic accuracy
of both used RDTs and XN-30 compared to uncorrected
microscopy (upper part) and qPCR (lower part). Consider-
ing all qPCR-confirmed cases, the sensitivity of XN-30
was significantly higher than pLDH (70.9% versus 60.2%,
p < .0001), while specificity was equal (both 99.6%, p =
1.0). Conversely, XN-30 had higher specificity (99.6% ver-
sus 87.7%, p < .0001) than HRP-2, while the sensitivity of
HRP-2 was higher than that of XN-30 (86.3% versus
70.9%, p < .001). The difference in sensitivity between
HRP-2 and XN-30 was mostly caused by sub-microscopic
parasitemia cases (median parasite density 0.45 p/μL; IQR
0.13–1.8), most of whom (64.0%) had been pre-treated
with antimalarials. This suggests that at least part of the
cases detected by HRP-2, but missed by XN-30, may have
Table 2 Cases of malaria detected per type of diagnostic, for all included patients (n = 916)
Total Children Adults
All ages 0–2 years 2–5 years 5–15 years > 15 years
n = 908 n = 266 n = 180 n = 127 n = 335
n (%) n (%) n (%) n (%) n (%)
Microscopy 240 (26.4) 88 (33.1) 75 (41.7) 36 (28.1) 41 (12.3)
RDT (minimal 1 test positive) 396 (43.6) 131 (49.3) 118 (65.6) 68 (53.1) 79 (23.7)
Both positive 212 (53.3) 86 (65.7) 68 (57.6) 30 (44.1) 28 (35.0)
Only HRP2 positive 175 (44.2) 44 (33.6) 49 (41.5) 35 (52.2) 47 (59.5)
Only pLDH positive 9 (2.3) 1 (0.8) 1 (0.9) 2 (2.9) 5 (6.3)
qPCR1 374 (41.2) 118 (44.4) 104 (57.8) 58 (45.3) 94 (28.1)
> 20 p/μL 218 (24.1) 84 (31.6) 75 (41.7) 29 (22.7) 30 (8.9)
> 1 and < 20 p/μL 74 (8.2) 14 (5.3) 12 (6.7) 18 (14.0) 30 (8.9)
> 0.05 and < 1 p/μL 81 (8.9) 20 (7.5) 17 (9.4) 11 (8.6) 33 (9.9)
XN-302,3 255 (28.0) 87 (32.7) 79 (43.9) 39 (30.7) 50 (14.9)
1Excluding six false negative PCRs, which were most likely false negative due to sample mix-up
2Excluding 71 patients with an abnormal scattergram, three of whom had positive malaria microscopy
3There were three false negative cases detected by microscopy but not detected by XN-30
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been based on remaining presence of antigens after a re-
cent malaria infection. Among microscopically confirmed
cases, XN-30 had an equal or higher sensitivity and higher
specificity than HRP-2 and pLDH.
We compared parasite densities as recorded by XN-30
with densities quantified by microscopy and qPCR. Fig-
ure 6 shows the corresponding correlations (microscopy
r = 0.82, p < .0001; qPCR r = 0.79, p < .0001). Follow-up
samples were available in 125 patients (51.9%) with
XN-30-confirmed malaria. The median parasite density
dropped from 19,138 p/μL (IQR 1594–98,165) at inclu-
sion to below the limit of positivity (20 p/μL) at
follow-up, confirming that XN-30 can be used for treat-
ment follow-up in a clinical setting. A total of 15 cases
of non-falciparum malaria parasitemia were identified
by microscopy, all of which were picked up by XN-30,
though they were not differentiated from P. falciparum.
Discussion
This is the first prospective clinical study to present the
diagnostic performance of XN-30. The sensitivity of
XN-30 to detect Plasmodium falciparum parasitemia
was superior to that of microscopy in qPCR-confirmed
cases, whereas the specificity was comparable. XN-30
had an equal or higher sensitivity than HRP-2 and pLDH
respectively, and a higher specificity than both for
microscopy-confirmed malaria. Our results are in line
with results from a recently published retrospective
study on the performance of the XN-30 from South Af-
rica [15]. The accuracy of malaria microscopy (LOD 24
p/μL) in the current study is far above the accuracy of
microscopy under field conditions, which is estimated at
50–100 p/μL [16]. The reported accuracy of XN-30
might therefore be an under-estimation compared to
most clinical settings. Commonly used RDTs have a de-
tection limit around 100–200 p/μL [17, 18], except when
the HRP-2 deletion of P. falciparum, as found in Central
Africa, is present that prevents the detection of this
strain [19].
In case of signs of severe malaria, follow-up of ad-
mitted malaria patients, or RDT-confirmed malaria
cases with persistent fever despite anti-malarial treat-
ment, the WHO recommends the use of malaria mi-
croscopy [20]. Our data suggest that XN-30 could be
used as an alternative microscopy in laboratories
where hematology analyzers are already used. XN-30
shares many of the advantages of microscopy, includ-
ing relatively low costs, quantification of parasite
Table 3 Diagnostic accuracy of XN-30 compared to malaria microscopy. Data with and without correction for qPCR confirmed sub-
microscopic parasitemia cases
XN-30, uncorrected (n = 837) XN-30, corrected* (n = 837)
Positive Negative Positive Negative
Positive microscopy 234 3 253 3
Negative microscopy 21 579 2 579
Sensitivity 98.7% 98.8%
Specificity 96.5% 99.7%
PPV 91.8% 99.2%
NPV 99.5% 99.5%
ROC 0.98 0.99
*In case of incongruent results between malaria microscopy and XN-30, the microscopy data was adjusted to the PCR result
Table 4 Prevalence of disease on qPCR, N (%, 95% CI) *McNemar test to compare sensitivity and specificity present. All ratios
presented as XN-30 relative to microscopy
XN-30 and microscopy versus qPCR results (n = 837)
XN-30 Microscopy Test ratio (95% CI) p value
Positive Negative Positive Negative
qPCR > 0.05 p/μL 253 104 237 120
qPCR < 0.05 p/μL 2 478 0 480
Sensitivity 70.9% 66.4% 0.94 (0.90–0.97) .0009
Specificity 99.6% 100.0% 0 .5
PPV 98.9% 100.0%
NPV 83.4% 80.0%
ROC 0.86 0.83
qPCR qualitative polymerase chain reaction, PPV positive predictive value, NPV negative predictive value
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density, and monitoring of treatment response. How-
ever, in contrast to microscopy, XN-30 can be used
by minimally trained staff, without sample prepar-
ation, has no observer-dependent viability, and is
available around-the-clock, whereas trained malaria
microscopists are often limitedly available. Another
important additional advantage of the XN-30 is that
it simultaneously provides a CBC with each analysis
and therefore synchronizes malaria diagnose and
management. Severe malaria anemia is a major cause
of death, and a delay of blood transfusion is associ-
ated with poor outcome [21].
Automated hematology analyzers to diagnose malaria
have been studied in the last two decades, applying
different techniques such as abnormal depolarization in
the granularity of phagocytes, abnormalities in the size
of blood cells, or blood cell differentiation patterns
[22–27]. However, these methods often carry limita-
tions such as low- and variable sensitivities and speci-
ficities due to technical limitations and confounding
Fig. 5 ROC curves XN-30 versus malaria microscopy and qPCR
Table 5 Prevalence of disease on microscopy (upper part of the table) and qPCR (lower part of the table), N (%, 95% CI) *McNemar
to compare sensitivity and specificity present ratio of proportions. All ratios presented as XN-30 relative to HRP-2 and pLDH
respectively
XN-30 and RDT (HRP-2 and pLDH) versus corrected microscopy results (n = 837)
XN-30 HRP-2 Test ratio p value pLDH Test ratio p value
Pos Neg Pos Neg 95% CI Pos Neg 95% CI
Microscopy positive 234 3 231 6 208 29
Microscopy negative 21 579 136 464 9 591
Sensitivity 98.7% 97.5% 0.99 (0.97–1.01) p = .45 87.8% 0.89 (0.85–0.93) p < .0001
Specificity 96.5% 77.3% 6.47 (4.31–9.73) p < .0001 98.5% 0.43 (0.23–0.81) p = .012
PPV 91.8% 62.9% 95.9%
NPV 99.5% 98.7% 95.3%
XN-30 and RDT (HRP-2 and pLDH) versus qPCR results (n = 837)
XN-30 HRP-2 Test ratio p value pLDH Test ratio p value
Pos Neg Pos Neg 95% CI Pos Neg 95% CI
qPCR > 0.05 p/μL 253 104 308 49 215 142
qPCR < 0.05 p/μL 2 478 59 421 2 478
Sensitivity 70.9% 86.3% 1.22 (1.15–1.29) < 0.0001 60.2% 0.85 (0.80–0.89) < .0001
Specificity 99.6% 87.7% 0.04 (0.01–0.14) < 0.0001 99.6% 1.0 (0.07–13.8) 1.0
PPV 99.2% 83.9% 99.1%
NPV 82.1% 89.6% 77.1%
Pos positive, neg negative, HRP2 histidine-rich protein 2, pLDH pan-Plasmodium lactate dehydrogenase, qPCR qualitative polymerase chain reaction, PPV positive
predictive value, NPV negative predictive value
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host- and pathology-specific differences [27, 28]. Direct
staining of malaria nucleic acid in parasites and
subsequent analysis by a flow cytometry-like technique
may prevent drawbacks from indirect tests [29–31].
Several studies have demonstrated that iRBC can be
detected through pigmented DNA or RNA strands
[32–34]. The XN-30 combines both techniques in a
fully automated manner. Since the analyzer can be
connected to WiFi, data could be instantaneously linked
to any organization involved in epidemiological research
and disease control.
The limit of detection as observed in the CHMI study
was lower than that of the diagnostic accuracy study (8.1
versus 20p/μL). We have no obvious explanation for this
difference; previous studies demonstrate that malaria
negative samples with low hemoglobin, high reticulocyte
count, thrombocytopenia or hemoglobinopathies had no
significant influence on the reliability of the malaria re-
sult [8]. Our data as presented in additional Table 1 sug-
gests that this may occur more frequently in very young
children and patients with malnutrition, but further re-
search is needed to analyze the origin of this difference.
Limitations
In the present study, XN-30 had an inconclusive result
due to an abnormal scatter gram distribution in 71 cases
(7.8%). This implies that when used in clinical settings, ap-
proximately one in 12 patients would need an additional
malaria diagnostic when the XN-30 is inconclusive. Sec-
ond, the XN-30 currently does not reliably distinguish
Plasmodium species prevalent in Burkina Faso. In
addition, this study was performed in a malaria hyperen-
demic setting; therefore, the population-level effect of the
sensitivity and specificity could vary by different settings
e.g. low-endemicity countries.
Conclusion
In conclusion, the XN-30 holds promise as a rapid and
sensitive test for malaria detection and subsequent treat-
ment monitoring. Since XN-30 provides a CBC with
each analysis, it provides critical information for malaria
management at a price comparable to CBC. Its higher
sensitivity compared to microscopy in low-density para-
sitemia also makes it a useful tool for mass screening in
control programs.
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Additional file 6: Figure S4. ROC curve at cutoff value of best fit, XN-30
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